Skip to main content

Press releases

2017-09-22
STOCKHOLM, September 22nd 2017, Moberg Pharma AB (OMX: MOB) appoints Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg’s Management Team, effective from today. Torbjörn Wärnheim has had this position at Moberg Pharma since 2013.
2017-09-01
STOCKHOLM, September 1st 2017, Moberg Pharma AB (OMX: MOB) announced that the Canadian Patent Office (CIPO) has issued Patent No. 2 860 373 which protects BUPI, currently in development for pain due to oral mucositis. This patent is expected to provide coverage through at least 2032.
2017-09-01
STOCKHOLM, August 31st 2017, Moberg Pharma AB (OMX: MOB) announces that the results from a phase 2-study with BUPI for the treatment of pain due to oral mucositis in patients with head and neck cancer have been published in the journal Pain Reports.
2017-08-28
STOCKHOLM, August 28th 2017, Moberg Pharma AB (OMX: MOB) has completed the divestment of the Fiber Choice® brand to Caret Pharma LLC. for a total consideration of $6.7 million plus the inventory value. The divestment results in a capital gain of circa $1.6 million.
2017-08-21
STOCKHOLM, August 21th 2017, Moberg Pharma AB (OMX: MOB) has entered into an agreement with Caret Pharma LLC. to divest the brand Fiber Choice® for a total consideration of $6.7 million plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $1.6 million. Divesting the brand enables Moberg Pharma to further focus resources on its core businesses.
2017-08-08
STOCKHOLM, August 8th 2017, Moberg Pharma AB (OMX: MOB) has corrected a minor error in the first text paragraph on page 8 of the Interim report for January – June 2017. A table figure (including comparison) was incorrectly stated in the referring text. This has been corrected and the updated version of the report has been published on the company’s web page.
2017-08-08
OUR THREE LARGEST BRANDS ARE DEVELOPING WELL "Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented," says Peter Wolpert, CEO Moberg Pharma.
2017-08-07
STOCKHOLM, August 7th 2017, Moberg Pharma AB (OMX: MOB) reports positive clinical data for Kerasal Nail®/ Emtrix®. The study shows that Kerasal Nail®/ Emtrix® produces a visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis. The results will be presented at EADV Geneva in September 2017, as well as being published in the journal Dermatology and is now available online at http://www.karger.com/DOI/10.1159/000478257.
2017-08-01
STOCKHOLM, August 1st, 2017 - On August 8th 2017, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - June 2017. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2017-06-30
STOCKHOLM, June 30th 2017, Moberg Pharma AB (OMX: MOB).  The number of shares and votes in Moberg Pharma AB (publ) (“Moberg Pharma”) has increased by 28,920 in June 2017. Therefore, there are in total 17,440,762 shares and votes in the company as of June 30th 2017.
2017-05-16
STOCKHOLM, MAY 16th, 2017. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Tuesday, May 16, 2017 in the Company´s premises in Bromma.
2017-05-09
CONTINUED STRONG GROWTH IN EBITDA  
2017-05-03
STOCKHOLM, May 3rd, 2017 - On May 9th 2017, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - March 2017. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2017-04-25
STOCKHOLM, April 25th 2017. Moberg Pharma AB (OMX: MOB) expands retail presence for a second Dermoplast® product in 7,500 CVS stores and 3,500 Walmart stores. Opening orders are expected to ship in April.
2017-04-11
Moberg Pharma´s Annual Report for 2016 has been published and is available on www.mobergpharma.com
2017-04-11
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, May 16, 2017 at 5:00 p.m. (CET) in the Company´s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2017-04-06
STOCKHOLM, April 6th, 2017. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2017.
2017-03-30
STOCKHOLM, March 30th 2017, Moberg Pharma AB (OMX: MOB).  Following a successful test launch in Japan, Moberg Pharma’s local partner CMIC Group initiates a national roll-out of Zanmira® Nail (Kerasal Nail®) in several major cities during the second quarter.
2017-02-16
STOCKHOLM, February 16th 2017. Moberg Pharma AB (OMX: MOB) announces that Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma.
2017-02-14
EBITDA TRIPLED IN THE FOURTH QUARTER
2017-02-08
STOCKHOLM, February 8th, 2017 - On February 14th 2017, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report for January - December 2016. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2017-01-18
STOCKHOLM, January 18th, 2017. Moberg Pharma AB (OMX: MOB) today announced that the New Skin® Spray SKU will be sold in 3,900 Walmart stores and in over 1,500 Walgreens stores. Opening orders expected to ship in mid-March.